Belvin Marcia's Form 4 filing
CytomX Therapeutics, Inc. (CTMX) · filed Sep 22, 2023
- Accession no.
- 0001610717-23-000299
- Filed
- Sep 22, 2023
- Trade date
- Sep 20-22, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $5.35K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Belvin MarciaCIK 0001970752 | Officer (SVP, Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 20, 2023 | Common Stock | AGrant or awardAcquired | +11,250 | $0.00 | $0 | 152,070 | Direct | |
| Sep 22, 2023 | Common Stock | SSaleDisposed | −4,119 | $1.30 | −$5,354.7 | 147,951 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.